Cytori Therapeutics Inc. (CYTX) unveiled a pact to commercialize the company's cell therapies for the cardiovascular, renal and diabetes markets in Australia and several Asian nations. Shares of Cytori soared 46% to $3.05 after hours, after the company said partner Lorem Vascular will pay up to $500 million in fees for a 30-year exclusive license to Cytori. http://bigcharts.marketwatch.com/quickchart/quickchart.asp?s...
WOW! CYTX hasn't seen 3 bucks since last year. Pretty impressive run.Calabogie
An interesting ticker, CYTX, broke out today.Happy New Year!
0Now that it's back to its support, it may get interesting again.~aj
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |